Holen I - Search Results

1

Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates.

Santini D, Caraglia M, Vincenzi B, Holen I, Scarpa S, Budillon A, Tonini G. Santini D, et al. Among authors: holen i. Nat Clin Pract Oncol. 2006 Jun;3(6):325-38. doi: 10.1038/ncponc0520. Nat Clin Pract Oncol. 2006. PMID: 16757970 Review.

2

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.

Santini D, Vincenzi B, Hannon RA, Brown JE, Dicuonzo G, Angeletti S, La Cesa A, Coleman RE, Tonini G, Budillon A, Caraglia M, Holen I. Santini D, et al. Among authors: holen i. Oncol Rep. 2006 May;15(5):1351-7. Oncol Rep. 2006. PMID: 16596210

3

Combined therapies of bone disease with bisphosphonates.

Syddall SP, Ottewell PD, Holen I. Syddall SP, et al. Among authors: holen i. Curr Pharm Des. 2010;16(27):2988-97. doi: 10.2174/138161210793563590. Curr Pharm Des. 2010. PMID: 20722617 Review.

4

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert US, Conte PF, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Hadji P, et al. Among authors: holen i. Ann Oncol. 2016 Mar;27(3):379-90. doi: 10.1093/annonc/mdv617. Epub 2015 Dec 17. Ann Oncol. 2016. PMID: 26681681 Free article. Review.

5

The anti-tumour activity of bisphosphonates.

Neville-Webbe HL, Holen I, Coleman RE. Neville-Webbe HL, et al. Among authors: holen i. Cancer Treat Rev. 2002 Dec;28(6):305-19. doi: 10.1016/s0305-7372(02)00095-6. Cancer Treat Rev. 2002. PMID: 12470981 Review.

6

Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells.

Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Neville-Webbe HL, et al. Among authors: holen i. Int J Cancer. 2005 Jan 20;113(3):364-71. doi: 10.1002/ijc.20602. Int J Cancer. 2005. PMID: 15455384 Free article.

7

Preclinical evidence for the effect of bisphosphonates and cytotoxic drugs on tumor cell invasion.

Woodward JK, Coleman RE, Holen I. Woodward JK, et al. Among authors: holen i. Anticancer Drugs. 2005 Jan;16(1):11-9. doi: 10.1097/00001813-200501000-00002. Anticancer Drugs. 2005. PMID: 15613899 Review.

8

Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro.

Woodward JK, Neville-Webbe HL, Coleman RE, Holen I. Woodward JK, et al. Among authors: holen i. Anticancer Drugs. 2005 Sep;16(8):845-54. doi: 10.1097/01.cad.0000175582.01446.6f. Anticancer Drugs. 2005. PMID: 16096432

9

Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro.

Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Neville-Webbe HL, et al. Among authors: holen i. Tumour Biol. 2006;27(2):92-103. doi: 10.1159/000092489. Epub 2006 Mar 24. Tumour Biol. 2006. PMID: 16582586

10

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

Winter MC, Holen I, Coleman RE. Winter MC, et al. Among authors: holen i. Cancer Treat Rev. 2008 Aug;34(5):453-75. doi: 10.1016/j.ctrv.2008.02.004. Cancer Treat Rev. 2008. PMID: 18423992 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

129 results

Search Page